The all-cash acquisition at a significant premium provides immediate and certain value for CPRX shareholders. The stock should trade near the deal price with a small spread reflecting closing risk (regulatory, shareholder vote). Monitor the proxy filing and HSR review timeline. The FIRDAPSE patent settlement removes a key overhang, extending IP protection to 2035.
CPRX drugs
CPRX drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · May 7 $31.17entry
- T+1 · 6mo ago −0.06%α −0.89% · $31.15
- T+5 · 6mo ago −0.03%α −1.54% · $31.16
- T+20 · 6mo ago +0.35%α −2.78% · $31.28
- T+60 · due 4mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Catalyst Pharmaceuticals has entered into a definitive agreement to be acquired by Angelini Pharma S.p.A. for $31.50 per share in cash, representing a total equity value of approximately $4.1 billion. The transaction, unanimously approved by both boards, is expected to close in Q3 2026 and provides a 28% premium to the 30-day VWAP. Separately, Catalyst resolved all pending FIRDAPSE patent litigation with Hetero, pushing generic entry to no earlier than January 2035.
Key Financial Metrics
Key Facts
- Acquisition price of $31.50 per share in cash, total equity value ~$4.1 billion
- 28% premium to 30-day VWAP as of April 22, 2026; 21% premium to unaffected closing price
- Closing expected in Q3 2026, subject to stockholder approval, HSR, and other conditions
- All directors and executive officers entered into voting agreements to support the merger
- Termination fee of ~$155.5 million payable by Catalyst under specified circumstances
- FIRDAPSE patent litigation with Hetero settled; generic entry no earlier than January 2035
- Merger not subject to financing condition; Angelini financing via cash and debt with BNP Paribas as coordinator
- J.P. Morgan provided fairness opinion to Catalyst's board
Financial Impact
Total equity value of approximately $4.1 billion at $31.50 per share cash consideration
Risk Factors
- Shareholder vote may not be obtained (though insider voting agreements cover a significant block)
- Regulatory delays or antitrust conditions could push closing beyond Q3 2026 or impose remedies
- Superior proposal could emerge during the go-shop period, triggering termination fee
- Integration risk post-close for Angelini as a new U.S. market entrant
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-210587 |
| Document: 0001193125-26-210587-index-headers.html | 0001193125-26-210587 |
| Document: 0001193125-26-210587-index.html | 0001193125-26-210587 |
| Document: 0001193125-26-210587.txt | 0001193125-26-210587 |
Track record
16 reports on CPRX
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +25.72% at T+60 after the Feb 25, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 No price data
- Aug 22, 202612w ago Institutional Cluster Mixed 5/10 No price data
- Jul 24, 202616w ago 15-12G Bearish 9/10 Entry $31.49 No price data
- Jul 17, 202617w ago EFFECT Bearish 5/10 Entry $31.49 No price data
- Jul 15, 202617w ago 25-NSE Bearish 9/10 Entry $31.49 No price data
- Jul 8, 202618w ago 8-K Bullish 6/10 Entry $31.47 No price data
- Jun 30, 202619w ago DEFA14A Neutral 3/10 Entry $31.44 No price data
- Jun 30, 202619w ago 8-K Neutral 4/10 Entry $31.44 No price data
- May 28, 202624w ago PREM14A Bullish 8/10 Entry $31.23 to $31.46 ▲ +0.74% +2.53% vs SPY
- May 12, 202626w ago DEFA14A Neutral 3/10 Entry $31.14 to $31.34 ▲ +0.64% +2.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers